Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on August 17th, 2016 by Christine de Vries - ScheideggerPharma R&D
“Last year, Vice President Biden said that with a new moonshot, America can cure cancer. Last month, he worked with this Congress to give scientists at the National Institutes of Health the strongest resources that they’ve had in over a decade. So tonight, I’m announcing a new national effort to get it done,” said President Obama in his final State of the Union address in January 2016.
Posted on August 15th, 2016 by Patricia MorganPharma R&D
Product testing is a necessary step in almost any industry, but in the pharmaceutical world, testing the safety and efficacy of drugs isn’t just a matter of getting a few people to ‘try it out’ – it’s a massive, tightly-regulated effort requiring extensive drug trials that include hundreds or thousands of participants. (more…)
Posted on August 12th, 2016 by Jeffrey Paul, PhDPharma R&D
The future is biomarkers. This is an often-cited phrase you will have heard at drug development symposia and printed in articles. The line reminds me of the film, The Graduate, where Mr. McGuire tells young Benjamin that there is a “great future in in plastics.” Biomarkers are the plastics for personalized medicine, (more…)
Posted on August 10th, 2016 by Patrick C. May, PH.D.Pharma R&D
I have just returned from the Alzheimer’s Association International Conference (AAIC16) in Toronto, Canada. Toronto is a beautiful cosmopolitan city and a perfect setting for scientists from across the globe to come and share their latest research on Alzheimer’s disease. (more…)
Predictions, Modelling and Simulations: Their role in R&D decision-making is more “what” than “how”?
Posted on August 8th, 2016 by Dr Andrew A. ParsonsPharma R&D
“Predictions are difficult, especially when they are about the future”, a statement attributed to the Noble laurate Niels Bohr is very true. Despite these difficulties, the Pharma industry has built a range of predictive models to understand a range of drug actions including toxicity, disposition, elimination and efficacy. (more…)
Posted on August 4th, 2016 by Dr. Makarand Jawadekar, Ph.DPharma R&D
One of the most heard buzzwords nowadays is “Big Data.” Big data is defined as the application of large amounts of data for extracting insights and understanding patterns, to drive informed decision-making. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.